Designed to Manage Hard-to-Heal Wounds, from Chronic to Acute ROSWELL, Ga. , Oct. 2, 2024 /PRNewswire/ -- StimLabs ® , a pioneering regenerative medicine company, announces the nationwide launch of Corplex P TM, the first and only medical device derived from human umbilical cord extracellular matrix (ECM).
In a significant milestone for wound care, Corplex P was cleared by the US Food and Drug Administration (FDA) in February 2024 , putting StimLabs in a class of its own as the first to receive a wound management 510(k) clearance for a human birth tissue product. Corplex P is a dehydrated human umbilical cord particulate (dHUCP) device designed for the management of hard-to-heal wounds. The primary benefits of the device are in its composition, configuration, and ability to regulate moisture exchange.
Corplex P's connective tissue matrix components include collagens, fibronectin, laminin proteoglycans, and glycosaminoglycans (GAGs). The proprietary processing technique that allows the preservation of these components differentiates Corplex P from many xenograft products whose processing techniques can result in the stripping of valuable GAGs and proteoglycans. 1 Its hydrophilic components, in particular hyaluronic acid, are key to the device's absorptive properties.
While the product composition gives Corplex P the ability to provide a moist wound environment, its particulate format enables further moisture management by allowing exudate to drain from the wound. The particul.
